FDA
-
-
-
-
-
-
-
Biomea Fusion (BMEA) Announces FDA Clearance of IND Application for BMF-219 in Type 1 Diabetes
-
-
-
-
-
-
-
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
-
-
-
-
-
-
-
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
-
-
-
-
-
-
-
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
BMF-219 Enters the Clinic for KRAS Solid Tumors
-
-
-
-
-
-
-
Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer
-
-
-
-
-
-
-
Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights
-
251,230 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All